根据最新的财务报表(Form-10K),Aspira Women's Health Inc 的总资产为 $5,净损失为 $-13
AWHL 的关键财务比率是什么?
Aspira Women's Health Inc 的流动比率是 0.62,净利 margin 为 -144.44,每股销售为 $0.63。
Aspira Women's Health Inc 的收入按细分市场或地理位置如何划分?
Aspira Women's Health Inc 最大收入来源是 Bio-analytic and Diagnostic Services,在最近的收益报告中收入为 9,154,000。就地区而言, United States 是 Aspira Women's Health Inc 的主要市场,收入为 9,154,000。
Aspira Women's Health Inc 是否盈利?
不,根据最新的财务报表,Aspira Women's Health Inc 的净损失为 $-13
Aspira Women's Health Inc 有负债吗?
是的,Aspira Women's Health Inc 的负债为 8
Aspira Women's Health Inc 的流通股有多少?
Aspira Women's Health Inc 的总流通股为 17.4
关键数据
前收盘价
$0.32
开盘价
$0.3451
当日区间
$0.28 - $0.36
52周范围
$0.02 - $0.71
交易量
28.5K
平均成交量
62.7K
股息收益率
--
每股收益(TTM)
-0.99
市值
$17.2M
什么是 AWHL?
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 66 full-time employees. The company went IPO on 2000-09-29. The firm's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.